NCT05658549 is a Phase 1, PHASE2 clinical trial of N-acetyl cysteine in COVID-19, sponsored by Universitas Sebelas Maret.

Who is sponsoring NCT05658549?

NCT05658549 is sponsored by Universitas Sebelas Maret.

What drugs are being tested in NCT05658549?

Interventions in NCT05658549: N-acetyl cysteine.

Is NCT05658549 still recruiting?

NCT05658549 is currently completed. Last updated 20 December 2022.

Last reviewed 2022-12-20 · How we verify

NCT05658549

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

Completed Phase 1, PHASE2 Last updated 20 December 2022

What this trial tests

Phase 1, PHASE2 trial testing N-acetyl cysteine in COVID-19 in 120 participants. Completed in 30 July 2021.

Timeline

1 May 2021

Primary endpoint
30 July 2021

30 July 2021

Quick facts

Lead sponsor	Universitas Sebelas Maret
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	quadruple
Primary purpose	treatment
Enrollment	120
Start date	1 May 2021
Primary completion	30 July 2021
Estimated completion	30 July 2021
Sites	1 location across Indonesia

Drugs / interventions tested

N-acetyl cysteine

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Universitas Sebelas Maret — full company profile →

Who can join

Adults 18 to 60, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The role of N-acetylcysteine in decreasing neutrophil-lymphocyte ratio in COVID-19 patients: A double-blind, randomized controlled trial.
Prabowo NA, Megantara MA, Apriningsih H. · · 2023 · cited 2× · PMID 38454976 · DOI 10.52225/narraj.v3i2.121

Verify or expand the search:

Other trials of N-acetyl cysteine

Trials testing the same drug.

NCT04381897 — Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome · Phase 2 · not yet recruiting
NCT06836128 — The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients · Phase 3 · recruiting
NCT06384833 — Combination of Vitamin C and N-Acetylcysteine to Improve Functional Outcome After Rotator Cuff Repair · Phase 4 · not yet recruiting
NCT06139952 — Ameliorating Contrast Induced Nephropathy After Coronary Angiography · Phase 4 · completed
NCT06115408 — Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma · Phase 2, PHASE3 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Universitas Sebelas Maret trials

Trials by the same sponsor.

NCT07475065 — The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy · Phase 2, PHASE3 · not yet recruiting
NCT07039682 — Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV · NA · not yet recruiting
NCT07380178 — The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis · NA · completed
NCT06871358 — The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients · NA · completed
NCT07121569 — Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05658549 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Sebelas Maret
Last refreshed: 20 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05658549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing